MPR

FDA Fast Tracks MTX-001 for Chronic Venous Leg Ulcer Treatment

A phase 2 trial is investigating MTX-001, an injectable regenerative therapy, for patients with noninfected venous leg ulcers.
MPR

FDA Weighs Giredestrant as Adjuvant Therapy for Early Breast Cancer

A New Drug Application for the investigational oral selective estrogen receptor degrader giredestrant has received Priority ...
MPR

ASCO: Intismeran Plus Pembrolizumab Ups RFS, DMFS in High-Risk Melanoma

Increased T-cell receptor clonality and novel clonotypes seen with intismeran plus pembrolizumab versus pembrolizumab alone.
Monthly Prescribing Reference

ASCO: GLP-1 Receptor Agonist Initiation Cuts Metastatic Progression Across Cancer Types

A total of 10,225 patients with stage I to III cancer who initiated GLP-1 RA therapy after diagnosis were identified for the trial. HealthDay News — Across multiple solid tumors, glucagon-like peptide ...